Development of the General Scale Observance for Chronic Diseases

Chronic Diseases Clinical Trial

— EGOMAC  

Official title:

Development of the General Scale Observance for Chronic Diseases (EGOMAC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02885129
• Other study ID #: PSS 2014/EGOMAC-GUILLEMIN/SR
• Status: Completed
• Phase: N/A
• First received: August 23, 2016
• Last updated: August 13, 2017
• Start date: June 2014
• Est. completion date: April 2017

Study information

• Verified date: August 2017
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main objective is to assess the measurement characteristics (validity, reproducibility) and the invariance of EGOMAC scale in a population of consultants in diabetology, cardiology and rheumatology hospital and liberal and hospital oncology and Infectious disease, by following the evolution of patient compliance at D0 and D15.

The second objective is to assess the sensitivity to change of scale EGOMAC following developments compliance 3 months.

Description:

During a routine appointment (D0), the patient filled a newsletter and a questionnaire to complete.

The doctor collects medical informations for the case report form.

At the end of the first consultation (D0), an additional EGOMAC scale and a stamped envelope is delivered to the patient by asking him to fill that scale to 15 days and return it by Post Office (reproducibility study).

Finally, a new scale will be addressed to the patient at the end of 3 months, which will return by Post Office too (stability study).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 397
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patient age of 18 years

• from routine patient counseling

• with at least one of these diseases : heart failure, hypertension, coronary disease, type 2 diabetes, osteoarthritis of the knee or hip, osteoporosis, inflammatory rheumatism (rheumatoid arthritis, spondyloarthropathy), cancer ( with only non-hormonal oral anti cancer treatments) and HIV.

• patient can read the French language in order to complete the self -administered questionnaire

• patient agreeing to participate in the study

Exclusion Criteria:

• patient treated for more than 3 conditions mentioned in the inclusion criteria (

• patient receiving no drug prescription or recommendation of lifestyle or diet (for example consultationpurely diagnostic ).

Related Conditions & MeSH terms

• Chronic Disease
• Chronic Diseases

Locations

Country	Name	City	State
France	Central hospital	Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	EGOMAC questionnaire		baseline
Primary	Change in EGOMAC questionnaire		15 days